Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis

Journal of Cystic Fibrosis

Volumn 16, Issue 3, 2017, Pages 358-366

  Nichols, Dave P ^a   Happoldt, Carrie L ^b   Bratcher, Preston E ^b   Caceres, Silvia M ^b,c   Chmiel, James F ^d   Malcolm, Kenneth C ^b,c   Saavedra, Milene T ^b,c   Saiman, Lisa ^e   Taylor Cousar, Jennifer L ^b,c   Nick, Jerry A ^b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e Department of Medicine   (United States)

Author keywords

Azithromycin; Clinical trial; Cystic fibrosis; Drug interaction; Inhaled antibiotics; MexXY; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

AZITHROMYCIN; AZTREONAM LYSINE; PLACEBO; TOBRAMYCIN; ANTIINFECTIVE AGENT; AZTREONAM;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; HUMAN; IN VITRO STUDY; INTRON; LUNG FIBROSIS; LUNG FUNCTION; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STRESS; COMPLICATION; DRUG ADMINISTRATION ROUTE; DRUG EFFECTS; DRUG INTERACTION; DRUG MONITORING; FEMALE; LUNG FUNCTION TEST; MALE; MICROBIOLOGY; PROCEDURES; PSEUDOMONAS INFECTION; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; AZTREONAM; CYSTIC FIBROSIS; DRUG ADMINISTRATION ROUTES; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; TOBRAMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85008222786     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.12.003     Document Type: Article

References (49)

1. [1] Mogayzel, P.J. Jr., Naureckas, E.T., Robinson, K.A., et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 187:7 (2013), 680–689.
2. [2] B.W. Ramsey, M.S. Pepe, Quan, J.M., Otto, K.L., Montgomery, A.B., Williams-Warren, J., Vasiljev-K, M., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis inhaled tobramycin study group. N Engl J Med 340 (1999), 23–30.
3. [3] Saiman, L., Marshall, B.C., Mayer-Hamblett, N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003), 1749–1756.
4. [4] Caceres, S.M., Malcolm, K.C., Taylor-Cousar, J.L., et al. Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. Antimicrob Agents Chemother 58:11 (2014), 6851–6860.
5. [5] Nichols, D.P., Caceres, S., Caverly, L., et al. Effects of azithromycin in Pseudomonas aeruginosa burn wound infection. J Surg Res 183:2 (2013), 767–776.
6. [6] Vaara, M., Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithermycin in gram-negative enteric bacteria. Antimicrob Agents Chemother 37 (1993), 354–356.
7. [7] McCoy, K.S., Quittner, A.L., Oermann, C.M., Gibson, R.L., Retsch-Bogart, G.Z., Montgomery, A.B., Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 178:9 (2008), 921–928.
8. [8] Nick, J.A., Moskowitz, S.M., Chmiel, J.F., et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc 11:3 (2014), 342–350.
9. [9] Hay, T., Fraud, S., Lau, C.H., Gilmour, C., Poole, K., Antibiotic inducibility of the mexXY multidrug efflux operon of Pseudomonas aeruginosa: involvement of the MexZ anti-repressor ArmZ. PLoS One, 8(2), 2013, e56858.
10. [10] Lau, C.H., Fraud, S., Jones, M., Peterson, S.N., Poole, K., Reduced expression of the rplU-rpmA ribosomal protein operon in mexXY-expressing pan-aminoglycoside-resistant mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 56:10 (2012), 5171–5179.
11. [11] Islam, S., Jalal, S., Wretlind, B., Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 10:10 (2004), 877–883.
12. [12] Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H., Nishino, T., Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44:12 (2000), 3322–3327.
13. [13] Saiman, L., Chen, Y., Gabriel, P.S., Knirsch, C., Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 46:4 (2002), 1105–1107.
14. [14] Lutz, L., Pereira, D.C., Paiva, R.M., Zavascki, A.P., Barth, A.L., Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm. BMC Microbiol, 12, 2012, 196.
15. [15] Happoldt, C., Chmiel, J., Mayer Hamblett, N., et al. Selective drug interaction between azithromycin and inhaled tobramycin; replication dataset and additional in vitro work [abstract 292 NACFC]. Pediatr Pulmonol, 50(S41), 2015, S301.
16. [16] Quittner, A.L., Buu, A., Messer, M.A., Modi, A.C., Watrous, M., Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 128:4 (2005), 2347–2354.
17. [17] Assael, B.M., Pressler, T., Bilton, D., et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 12:2 (2013), 130–140.
18. [18] Quittner, A.L., Modi, A.C., Wainwright, C., Otto, K., Kirihara, J., Montgomery, A.B., Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 135:6 (2009), 1610–1618.
19. [19] Alhede, M., Kragh, K.N., Qvortrup, K., et al. Phenotypes of non-attached Pseudomonas aeruginosa aggregates resemble surface attached biofilm. PLoS One, 6(11), 2011, e27943.
20. [20] Caughlan, R.E., Sriram, S., Daigle, D.M., et al. Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression. Antimicrob Agents Chemother 53:12 (2009), 5015–5021.
21. [21] 2015 annual data report. 2015, Cystic Fibrosis Foundation Patient Registry.
22. [22] Nichols, D.P., Kuk, K.N., Nick, J.A., Drug interactions and treatment burden as survival improves. Curr Opin Pulm Med 21:6 (2015), 617–625.
23. [23] Lin, L., Nonejuie, P., Munguia, J., et al. Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant gram-negative bacterial pathogens. EBioMedicine 2:7 (2015), 690–698.
24. [24] Buyck, J.M., Plesiat, P., Traore, H., Vanderbist, F., Tulkens, P.M., Van Bambeke, F., Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability. Clin Infect Dis 55:4 (2012), 534–542.
25. [25] Aubert, J.D., Juillerat-Jeanneret, L., Fioroni, P., Dayer, P., Plan, P.A., Leuenberger, P., Function of human alveolar macrophages after a 3-day course of azithromycin in healthy volunteers. Pulm Pharmacol Ther 11:4 (1998), 263–269.
26. [26] Baumann, U., King, M., App, E.M., et al. Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can Respir J 11:2 (2004), 151–155.
27. [27] Beringer, P., Huynh, K.M., Kriengkauykiat, J., et al. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob Agents Chemother 49:12 (2005), 5013–5017.
28. [28] Gladue, R.P., Bright, G.M., Isaacson, R.E., Newborg, M.F., In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 33:3 (1989), 277–282.
29. [29] Saiman, L., Mehar, F., Niu, W.W., et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 23:3 (1996), 532–537.
30. [30] Moskowitz, S.M., Foster, J.M., Emerson, J.C., Gibson, R.L., Burns, J.L., Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother 56:5 (2005), 879–886.
31. [31] Aaron, S.D., Vandemheen, K.L., Ferris, W., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366:9484 (2005), 463–471.
32. [32] Jeannot, K., Sobel, M.L., El Garch, F., Poole, K., Plesiat, P., Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction. J Bacteriol 187:15 (2005), 5341–5346.
33. [33] Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H., Nishino, T., Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44:9 (2000), 2242–2246.
34. [34] Gillis, R.J., White, K.G., Choi, K.H., Wagner, V.E., Schweizer, H.P., Iglewski, B.H., Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 49:9 (2005), 3858–3867.
35. [35] Sugimura, M., Maseda, H., Hanaki, H., Nakae, T., Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. Antimicrob Agents Chemother 52:11 (2008), 4141–4144.
36. [36] Beigelman, A., Isaacson-Schmid, M., Sajol, G., et al. Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 135:5 (2015), 1171–1178.
37. [37] Ratjen, F., Saiman, L., Mayer-Hamblett, N., et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 142:5 (2012), 1259–1266.
38. [38] Saiman, L., Mayer-Hamblett, N., Anstead, M., et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol 47:7 (2012), 641–648.
39. [39] Gielen, V., Johnston, S.L., Edwards, M.R., Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 36:3 (2010), 646–654.
40. [40] Saiman, L., Anstead, M., Mayer-Hamblett, N., et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 303 (2010), 1707–1715.
41. [41] Hoffmann, N., Lee, B., Hentzer, M., et al. Azithromycin blocks quorum sensing and alginate polymer formation an dincreases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in cftr(−/−) mice. Antimicrob Agents Chemother 51 (2007), 3677–3687.
42. [42] Tramper-Stranders, G.A., Wolfs, T.F., Fleer, A., Kimpen, J.L., van der Ent, C.K., Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 26 (2007), 8–12.
43. [43] Cigana, C., Nicolis, E., Pasetto, M., Assael, B.M., Melotti, P., Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 350 (2006), 977–982.
44. [44] Verleden, G.M., Vanaudenaerde, B.M., Dupont, L.J., VanRaemdonck, D.E., Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 174 (2006), 566–570.
45. [45] Equi, A., Balfour-Lynn, I.M., Bush, A., Rosenthal, M., Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360:9338 (2002), 978–984.
46. [46] Samson, C., Tamalet, A., Thien, H.V., et al. Long-term effects of azithromycin in patients with cystic fibrosis. Respir Med 117 (2016), 1–6.
47. [47] Willekens, J., Eyns, H., Malfroot, A., How long should we maintain long-term azithromycin treatment in cystic fibrosis patients?. Pediatr Pulmonol 50:1 (2015), 103–104.
48. [48] Matzneller, P., Krasniqi, S., Kinzig, M., et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrob Agents Chemother 57:4 (2013), 1736–1742.
49. [49] Wilms, E.B., Touw, D.J., Heijerman, H.G., Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther Drug Monit 28:2 (2006), 219–225.